Kierstead R W, Faraone A, Mennona F, Mullin J, Guthrie R W, Crowley H, Simko B, Blaber L C
J Med Chem. 1983 Nov;26(11):1561-9. doi: 10.1021/jm00365a004.
A series of binary (aryloxy)propanolamines has been prepared and examined in vitro and in vivo for beta-adrenoreceptor blocking activity. These symmetrical compounds consist of two (S)-(phenyloxy)propanolamine pharmacophores coupled through alkylenedioxy or poly(oxyethylenedioxy) linking units of varying lengths. Examples of such binary compounds linked through the 2,2', 3,3', and 4,4' positions in the aromatic rings of the pharmacophores have been prepared. In vitro and in vivo test data indicate that the 2,2' compounds tend to be selective beta 2-adrenergic blocking agents, the 4,4' binaries tend to be selective beta 1-blocking agents, and those compounds with 3,3' linkages exhibit intermediate selectivities. One of the 4,4'-linked binary compounds, 4s, exhibited potent, cardioselective beta-blockade in vivo, which was of short duration and was accompanied by a prolonged tachycardia.
已制备了一系列二元(芳氧基)丙醇胺,并在体外和体内对其β-肾上腺素能受体阻断活性进行了研究。这些对称化合物由两个通过不同长度的亚烷基二氧基或聚(氧乙烯二氧基)连接单元偶联的(S)-(苯氧基)丙醇胺药效基团组成。已经制备了通过药效基团芳环中2,2'、3,3'和4,4'位置连接的此类二元化合物的实例。体外和体内测试数据表明,2,2'化合物倾向于为选择性β2-肾上腺素能阻断剂,4,4'二元化合物倾向于为选择性β1-阻断剂,而具有3,3'连接的那些化合物表现出中间选择性。其中一种4,4'-连接的二元化合物4s在体内表现出强效、心脏选择性β-阻断作用,作用持续时间短,并伴有长时间的心动过速。